Rain Therapeutics Inc expected to post a loss of 70  cents a share - Earnings Preview

Rain Oncology

03/05/2022 03:06

* Rain Therapeutics Inc  RAIN.OQ   RAIN.O  is expected
to report
results on May 4.
    * ​Refinitiv's mean analyst estimate for Rain Therapeutics
Inc is
for a loss of 70 cents per share. For the same quarter last
year, the company reported a loss of $1.93 per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Rain
Therapeutics
Inc is $20​, above​ its last closing price of $4.03. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.53       -0.56      -0.68     Missed  -20.7
 Sep. 30 2021  -0.41       -0.48      -0.70     Missed  -45.5
 Jun. 30 2021  -0.60       -0.60      -0.39     Beat    34.8​
 Mar. 31 2021  -0.78       -0.78      -1.93     Missed  -147.4
 ​​                                                     
                                                        ​
 This summary was machine generated May 3 at 02:06 GMT.  All
figures in US dollars  unless otherwise stated